A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein @entity165 -lowering ability of XXXX 10, 20, and 40 mg/d with @entity5470 20 and 40 mg/d.

@entity1 @entity1007 @entity5470 @entity1674 @entity5753 @entity165
BACKGROUND: The available statin drugs have similar pharmacodynamic properties but are not equal in low-density lipoprotein @entity165 (LDL-C)-lowering efficacy. OBJECTIVE: The aim of this study was to compare the effects of @entity5753 and @entity5470 in lowering LDL-C. METHODS: This was a prospective, randomized, double-blind study of @entity1 aged >20 years with @entity1007 conducted at 44 clinical sites across the United States. After a 6-week National @entity165 Education Program (NCEP) Step I diet lead-in period in @entity1 taking lipid-lowering drugs at screening, @entity1 were randomized to receive @entity5753 10, 20, or 40 mg/d or @entity5470 20 or 40 mg/d (the doses available at the time the study was conducted) for 6 weeks. @entity1 not taking lipid-lowering drugs at screening and who had been following the Step I diet for at least 6 weeks proceeded to the treatment phase. All @entity1 received instruction for a Step I diet, which they followed throughout the treatment phase. After the treatment period, total @entity165 (TC), high-density lipoprotein @entity165 (HDL-C), LDL-C, and @entity1674 were measured, and TC:HDL-C and LDL-C:HDL-C ratios were calculated. RESULTS: A total of 838 @entity1 (476 @entity1 , 362 @entity1 ; mean [SD] age, 59 [12] years) were included in the study. @entity5753 20 and 40 mg/d significantly reduced mean LDL-C compared with the same dosages of @entity5470 . TC and the LDL-C:HDL-C ratio decreased more with @entity5753 than with @entity5470 at a given dose level. Approximately 50% of @entity1 treated with @entity5753 20 and 40 mg/d compared with approximately 25% treated with @entity5470 20 and 40 mg/d reached NCEP Adult Treatment Panel II LDL-C goals. CONCLUSION: In this small study population of @entity1 with @entity1007 taking lipid-lowering drugs, short-term (6-week) treatment with @entity5753 was more efficacious than @entity5470 in lowering @entity165 levels and reaching LDL-C treatment goals.
